PARIS, April 8, 2013 — /PRNewswire/ — GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a €32 million Series A financing. The financing was co-led by Novartis Venture…
Blog Archives
GenSight Biologics announces closing of €32 million (~$41 Million) Series A financing to Advance Gene Therapy for Blinding Disease
Roche and Isis Pharmaceuticals form alliance for Huntington’s disease
BASEL, Switzerland, and CARLSBAD, Calif., April 8, 2013 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) and Isis Pharmaceuticals, Inc (ISIS) today announced that they have formed an alliance to develop treatments for Huntington’s disease (HD) based on Isis’ antisense…
Sanofi to Invest USD 75 million in a New Manufacturing Facility in Vietnam
Paris, France – March, 29, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) announces today the official launch of a construction project for a new manufacturing facility in the Saigon High Tech Park – Ho Chi Minh City, during a…
European Society for Medical Oncology (ESMO) selects Nice for its second office in Europe
On Thursday 7th February, the European Society for Medical Oncology will open its new offices in Nice’s Arénas district. Founded 35 years ago in Nice and today based in Lugano (Switzerland), ESMO (the European Society for Medical Oncology) is the…
MEDIAN Technologies awarded € 1.4 million contract
Press release Sophia Antipolis, France MEDIAN Technologies has been selected to provide its imaging solutions in a phase II clinical trial sponsored by a leading biopharmaceutical company. MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service…
Congratulations to Magda Marquet & Francois Ferré as Japan’s Ajinomoto Acquires Contract Drug Maker Althea Technologies for about $175 million !!!
Source: Althea News 3.6.2013 – Ajinomoto Co., Inc. Agrees to Acquire Althea Technologies, Inc. Acquisition Expected to Give Ajinomoto Co., Inc. Entry Into the Contract Development and Manufacturing Market SAN DIEGO – March, 6, 2013 — Ajinomoto Co., Inc. (“Ajinomoto…
UPDATED Sad news for San Diego: Pfizer closes down CovX
Sad Rumor for the San Diego Biotech world: we heard last Friday morning that Pfizer’s head of R&D would have announced to the CovX employees, Pfizer’s decision to close down the CovX site in order to minimize expenses and focus…
Annual venture investment dollars decline for first time in three years, according to the MoneyTree report
Source: pcw Notable lower levels in clean technology and life sciences sectors; investors shift from seed to early stages in 2012 Washington, D.C., January 18, 2013 – Venture capitalists invested $26.5 billion in 3,698 deals in 2012, a decrease of…
French Biotech Transgene Won’t Sign TG4040 Partnership Soon, CEO Says
Save the date: NeuroConnection, Marseille, July 1-2, 2013
To develop new partnerships in Neurosciences Save the Date ! July 1-2, 2013, Marseille (European Capital of Culture 2013) welcomes an international event around technological innovation and private-public partnerships in NEUROSCIENCES. French life science cluster Eurobiomed organizes this event in…
